VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Up 9,129.5% in January

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 774,911 shares, an increase of 9,129.5% from the January 15th total of 8,396 shares. Based on an average daily trading volume, of 9,185,858 shares, the short-interest ratio is currently 0.1 days. Currently, 30.5% of the shares of the stock are short sold. Currently, 30.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,185,858 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

VivoSim Labs Stock Down 1.5%

Shares of NASDAQ:VIVS traded down $0.03 during midday trading on Tuesday, hitting $1.92. The stock had a trading volume of 112,439 shares, compared to its average volume of 3,630,930. The company’s 50-day moving average price is $2.08 and its 200-day moving average price is $2.37. VivoSim Labs has a fifty-two week low of $1.41 and a fifty-two week high of $21.96. The company has a market capitalization of $5.01 million, a P/E ratio of -0.44 and a beta of 1.21.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The firm had revenue of $0.03 million during the quarter.

Hedge Funds Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by institutional investors and hedge funds.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.